Article By:
BioMedReports
Friday, January 9, 2015 5:13 PM EDT
NRX has announced that the Company has received positive Scientific Advice from the European Medicines Agency (EMA) regarding their Phase 3 program with Pyridorin® in diabetic nephropathy.
In this article: NRX
